Replies to post #58429 on Biotech Values

[DewDiligence]

2Q08 Sustiva sales: $282M ($1.1B annualized), +21% vs 2Q07, +3% vs 1Q08:

http://biz.yahoo.com/bw/080724/20080724005186.html

Growth is coming almost entirely from increased demand for Atripla, the combination pill that includes Sustiva, Viread, and Emtriva.